ATE397019T1 - Herstellung von f(ab')2 fragmenten in saügetierzelle - Google Patents

Herstellung von f(ab')2 fragmenten in saügetierzelle

Info

Publication number
ATE397019T1
ATE397019T1 AT02789019T AT02789019T ATE397019T1 AT E397019 T1 ATE397019 T1 AT E397019T1 AT 02789019 T AT02789019 T AT 02789019T AT 02789019 T AT02789019 T AT 02789019T AT E397019 T1 ATE397019 T1 AT E397019T1
Authority
AT
Austria
Prior art keywords
fragments
preparation
mammal cells
cells
antibody fragments
Prior art date
Application number
AT02789019T
Other languages
English (en)
Inventor
Abraham Bout
David Jones
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Application granted granted Critical
Publication of ATE397019T1 publication Critical patent/ATE397019T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624Disulfide-stabilized antibody (dsFv)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/10Plasmid DNA
    • C12N2800/108Plasmid DNA episomal vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00Vectors comprising a special translation-regulating system
    • C12N2840/20Vectors comprising a special translation-regulating system translation of more than one cistron
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT02789019T 2001-12-17 2002-12-17 Herstellung von f(ab')2 fragmenten in saügetierzelle ATE397019T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL0100917 2001-12-17

Publications (1)

Publication Number Publication Date
ATE397019T1 true ATE397019T1 (de) 2008-06-15

Family

ID=19760784

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02789019T ATE397019T1 (de) 2001-12-17 2002-12-17 Herstellung von f(ab')2 fragmenten in saügetierzelle

Country Status (11)

Country Link
US (2) US20050048038A1 (de)
EP (1) EP1456238B1 (de)
AT (1) ATE397019T1 (de)
AU (1) AU2002353662B2 (de)
CA (1) CA2470579C (de)
DE (1) DE60226896D1 (de)
DK (1) DK1456238T3 (de)
ES (1) ES2307807T3 (de)
NZ (1) NZ533332A (de)
SI (1) SI1456238T1 (de)
WO (1) WO2003051927A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US7527961B2 (en) 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
NZ533124A (en) 2001-12-07 2005-11-25 Crucell Holland B Production of viruses, viral isolates and vaccines
DE60226896D1 (de) 2001-12-17 2008-07-10 Crucell Holland Bv Herstellung von f(ab')2 fragmenten in saügetierzelle
CN100383238C (zh) 2003-05-09 2008-04-23 克鲁塞尔荷兰公司 E1-永生化的细胞培养物及培养所述细胞以提高从中获取的产物产量的方法
MA49426B1 (fr) 2017-10-02 2022-09-30 Laboratorios Silanes S A De C V Processus à haut rendement pour la production d’antivenins à partir de fragments d’anticorps f(ab') 2
WO2023205656A2 (en) * 2022-04-18 2023-10-26 John Paul Ii Medical Research Institute Immortalized cells for production of bioproducts, methods of producing bioproducts with an immortalized cell, and methods of making immortalized cells for production of bioproducts

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4624846A (en) * 1983-07-29 1986-11-25 Immunomedics, Inc. Method for enhancing target specificity of antibody localization and clearance of non-target diagnostic and therapeutic principles
DE3584341D1 (de) * 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
US5168062A (en) * 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
DE3920358A1 (de) * 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0604580A1 (de) * 1991-09-19 1994-07-06 Genentech, Inc. Expression in E.Coli von Antikörperfragmenten mit mindestens einem cystein in freier -SH Form. Anwendung in der Herstellung bifunktioneller Antikörper.
ATE445705T1 (de) * 1995-06-15 2009-10-15 Crucell Holland Bv Verpackungssysteme für humane rekombinante adenoviren zur gentherapie
ES2237420T5 (es) * 1999-04-15 2010-03-03 Crucell Holland B.V. Produccion de proteina recombinante en una celula humana.
EP1103610A1 (de) 1999-11-26 2001-05-30 Introgene B.V. Impfstoffherstellung von immortalisierten Säugetierzellinien
EP1130099A1 (de) * 2000-02-25 2001-09-05 Crucell Holland B.V. Aktiviertes Vitronektin als Angiogenesemarker nachgewiesen durch Phagen-Antikörper
DE60226896D1 (de) 2001-12-17 2008-07-10 Crucell Holland Bv Herstellung von f(ab')2 fragmenten in saügetierzelle

Also Published As

Publication number Publication date
ES2307807T3 (es) 2008-12-01
CA2470579C (en) 2012-03-06
AU2002353662B2 (en) 2009-04-23
US7537916B2 (en) 2009-05-26
US20050048038A1 (en) 2005-03-03
NZ533332A (en) 2005-07-29
SI1456238T1 (sl) 2008-08-31
EP1456238B1 (de) 2008-05-28
CA2470579A1 (en) 2003-06-26
AU2002353662A1 (en) 2003-06-30
EP1456238A2 (de) 2004-09-15
WO2003051927A2 (en) 2003-06-26
US20080166767A1 (en) 2008-07-10
DE60226896D1 (de) 2008-07-10
DK1456238T3 (da) 2008-08-18
WO2003051927A3 (en) 2003-11-20

Similar Documents

Publication Publication Date Title
EP1362093A4 (de) Schnellproduktion monoklonaler antikörper
TR200300478T2 (tr) Hümanize antiLT-ß-R antikorları
ATE397019T1 (de) Herstellung von f(ab')2 fragmenten in saügetierzelle
DE60040012D1 (de) Rekombinantes gelatin in impstoffen
ATE430580T1 (de) Glycoprotein-zusammensetzungen
TR200102338T2 (tr) Siklik ikame edilmiş bağlı pirolokarbazoller ve izoindolonlar.
IL162648A0 (en) Cellular compositions and methods of making and using them
BR0015224A (pt) Anticorpo anti-antìgeno de célula estaminal prostática (psca) isolado, anticorpo monoclonal anti-psca, ácido nucleico isolado, vetor de expressão, célula, célula hospedeira, método de produção de anticorpo, composição método in vitro para matar uma célula cancerosa que expresse psca, uso de uma anticorpo monoclonal anti-psca e artigo industrializado
DK1157037T3 (da) GCSF-konjugater
ATE500323T1 (de) Subtilisin-variante
DK1210411T3 (da) Sammensætninger og fremgangsmåder til forbedret celledyrkning
DE69734605D1 (de) Abgeschwächter salmonellenstamm, gebraucht als vehikel zur oralen immunisierung
DK1379671T3 (da) Fremgangsmåder til dyrkning af circovirus
FR15C0055I1 (de)
BR0113162A (pt) Ariloxialquilaminas nao-imidazóis
BR0215266A (pt) Preparação liofilizada compreendendo anticorpos contra o receptor de egf
ATE380822T1 (de) Funf-helix protein
BR0009964A (pt) Peptìdios artificiais com atividade desuperfìcie e sua utilização na preparação de surfactante artificial
EA200201214A1 (ru) Замещенные тиоацетамиды
IL172854A0 (en) Autologous self-tolerance inducing cells of monocytic origin and their use in pharmaceutical preparations
NO20031860L (no) Kahalalid F
NO20061470L (no) Fremgangsmate for fremstilling av gamma-karboksylerte proteiner
PL367306A1 (pl) Szczepionki na bazie autologicznych komórek T i sposoby ich otrzymywania
BR0013221A (pt) Chá preto de folha
TR200401462T4 (tr) Torsemid modifikasyonu II' yi içeren dengeli bir farmasötik formülasyonu

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1456238

Country of ref document: EP